Background. According to large epidemiological studies, a link has been established between hyperuricemia (HU) and a high risk of cardiovascular diseases, including serious cardiovascular events such as stroke and coronary heart disease. Asymptomatic or secondary HU, without clinical signs of joint syndrome, can last for years and be a random finding during examination, most often with the development of complications from the cardiovascular system. Therefore, it is important to know the risk factors leading to this pathological condition and correct them in a timely manner at the primary level. In this literature review, the probable causal risk factors for secondary hypertension (HT) are considered, in particular obesity, dyslipidemia, long-term administration of low doses of acetylsalicylic acid and loop diuretics. Aim: Systematic analysis of international and domestic experience of studying the risk factors of HU in HT. Search strategy: A systematic search was carried out in the electronic databases PubMed, Cochrane library, e-library, Cyberleninka we also looked at the additional information resource Google Scholar. The inclusion criteria were: reports on randomized and cohort studies conducted on large populations, meta-analyses and systematic reviews, original full-text articles in English and Russian that are publicly available and contain statistically confirmed conclusions. Exclusion criteria: summary reports, newspaper articles and personal messages. The search depth was 10 years (2012-2022). Relevant search returned 4100 articles; after initial analysis, 52 articles were selected for final analysis in accordance with the inclusion criteria. Results: According to the results of our literature review, most studies indicate the influence of risk factors such as obesity, dyslipidemia, long-term use of low doses of acetylsalicylic acid and loop diuretics on the development of asymptomatic HU in patients with HT.
Saule T. Abisheva1, https://orcid.org/0000-0001-6260-8220 Tansholpan E. Batyrkhan1, https://orcid.org/0000-0002-3359-295X Tatyana V. Vinnik1,2, https://orcid.org/0000-0001-5019-9829 1 NCJSC «Astana Medical University», Astana c., Republic of Kazakhstan; 2 Ariel University, Ariel, Israel.
1. Головач И.Ю. и соавторы. Бессимптомная гиперурикемия: тайные взаимосвязи, невидимые эффекты и потенциальные осложнения // Научно-практическая ревматология. 2020. 58(6):725–733. 2. Кобалава Ж.Д. Бессимптомная гиперурикемия: подходы к лечению в аспекте риска развития сердечно-сосудистых и почечных заболеваний // Кардиология. 2020. 60(12):104-109. 3. Кудабаева Х.И. и соавт. Бессимптомная гиперурикемия у взрослых в экологически неблагополучных районах Актюбинской области // Медицинский журнал Западного Казахстана. 2018. 57 (1), 4-9. 4. Фомин В.В. и соавторы Гиперурикемия, подагра и высокий кардиоваскулярный риск – как ими управлять в клинической практике // Терапевтический архив. 2019. 91 (12): 75–83. 5. Agarwal V., Hans N., Messerli F.H. Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis // The Journal of Clinical Hypertension. 2013. № 6 (15). C. 435–442. 6. Ajani U. A. et al. Aspirin Use Among U.S. Adults // American Journal of Preventive Medicine. 2016. № 1 (30). C. 74–77. 7. Akinwusi P. O. et al. Low dose aspirin therapy and renal function in elderly patients // International Journal of General Medicine. 2013. (6). C. 19–24. 8. Ali N. et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults // PLOS ONE. 2018. №11 (13). C. e0206850. 9. Andrés M. et al. Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study // Arthritis & Rheumatology. 2016. №6 (68). C. 1531–1539. 10. Billa G., Dargad R., Mehta A. Prevalence of Hyperuricemia in Indian Subjects attending Hyperuricemia Screening Programs-A Retrospective Study // The Journal of the Association of Physicians of India. 2018. № 4 (66). C. 43–6. 11. Biscaglia S. et al. Uric acid and coronary artery disease: An elusive link deserving further attention // International Journal of Cardiology. 2016. (213). C. 28–32. 12. Chen J.H. et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: A prospective study // Arthritis Care & Research. 2013. №1 (65). C. 133–140. 13. Choi H.K., Mount D.B., Reginato A.M. Pathogenesis of Gout // Annals of Internal Medicine. 2015. №7 (143). C. 499. 14. Derosa G., Maffioli P., Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials // Pharmacological Research. 2015. (102). C. 63–70. 15. Dong H. et al. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes // Scientific Reports. 2017. № 1(7). C. 8822. 16. Dong J. et al. Triglyceride-glucose index is a predictive index of hyperuricemia events in elderly patients with hypertension: a cross-sectional study // Clinical and Experimental Hypertension. 2022. №1 (44). C. 34–39. 17. Gómez M. et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population // Atherosclerosis. 2014. №1 (232). C. 134–140. 18. Gonçalves J.P. et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome // Endocrine. 2012. №3 (41). C. 450–457. 19. Gong M. et al. Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications // Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020. (Volume 13). C. 943–962. 20. Hamada T. et al. A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension // Clinical and Experimental Hypertension. 2014. №4 (36). C. 251–257. 21. Higgins P. et al. Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta-Analysis // Cardiovascular Therapeutics. 2012. № 4 (30). C. 217–226. 22. Kim I. Y. et al. Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men // Journal of Clinical Medicine. 2019. № 6 (8). С. 837-841 23. Kim S. Y. et al. Hyperuricemia and risk of stroke: A systematic review and meta-analysis // Arthritis & Rheumatism. 2019. № 7 (61). C. 885–892. 24. Kuwabara M. et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension // Hypertension Research. 2014. № 8 (37). C. 785–789. 25. Landsberg L. et al. Obesity-Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment // The Journal of Clinical Hypertension. 2013. №1 (15). C. 14–33. 26. Li J.-R., Fan Y., Liu M.-L. Association Between Low-Dose Aspirin and Uric Acid in the Elderly: An Observational Retrospective Cross-Sectional Study. // International journal of general medicine. 2021. (14). C. 3635–3643. 27. Li M. et al. Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies // Atherosclerosis. 2014. № 2 (232). C. 265–270. 28. Liu F. et al. Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008–2012) // Lipids in Health and Disease. 2020. №1 (19). C. 58. 29. Loeffler L.F. et al. Uric Acid Level and Elevated Blood Pressure in US Adolescents // Hypertension. 2012. № 4 (59). C. 811–817. 30. Mancia G, Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Redon J, Stack AG, Tsioufis KP. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020, Oct C. 80:1-11. 31. Maloberti A. et al. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study // Journal of Hypertension. 2021. №2 (39). C. 333–340. 32. McAdams DeMarco M. A. et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study // Arthritis & Rheumatism. 2012. №1 (64). C. 121–129. 33. Musini V.M. et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension // Cochrane Database of Systematic Reviews. 2014 May 29;(5):CD003824. 34. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. // Lancet (London, England). 2016. № 10026 (387). C. 1377–1396. 35. Ni Q. et al. Risk factors for the development of hyperuricemia A STROBE-compliant cross-sectional and longitudinal study. Medicine (Baltimore). 2019 Oct. 98(42):e17597. 36. Prabhakaran D. et al. Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition // The Lancet. 2018. № 10126 (391). C. 1224–1236. 37. Rahimi-Sakak F. et al. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants // BMC Cardiovascular Disorders. 2019. №1 (19). C. 218. 38. Raja R. et al. Hyperuricemia Associated with Thiazide Diuretics in Hypertensive Adults // Cureus. 2019. Aug 22. 11(8):e5457. 39. Richette P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout // Annals of the Rheumatic Diseases. 2017. №1(76). C.29–42. 40. Scott J.T., Higgens C.S. Diuretic induced gout: a multifactorial condition. // Annals of the Rheumatic Diseases. 2019. № 2 (51). C. 259–261. 41. Smith EM. L. Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies // Arthritis Rheumatol. 2015. № 3 (67). C. 134–140. 42. Stewart D.J., Langlois V., Noone D. Hyperuricemia and Hypertension: Links and Risks // Integrated Blood Pressure Control. 2019. (Volume 12). C. 43–62. 43. Tan P. K., Ostertag T. M., Miner J. N. Mechanism of high affinity inhibition of the human urate transporter URAT1 // Scientific Reports. 2016. № 1 (6). C. 34995. 44. Wei L. et al. Impact of allopurinol use on urate concentration and cardiovascular outcome // British Journal of Clinical Pharmacology. 2012. № 4 (71). C. 600–607. 45. Williams B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension // European Heart Journal. 2018. №33 (39). C. 3021–3104. 46. Xiong Y. et al. Positive association between body fat percentage and hyperuricemia in patients with hypertension: The China H-type hypertension registry study // Nutrition, Metabolism and Cardiovascular Diseases. 2021. №11 (31). C. 3076–3084. 47. Yamada A. et al. Association of Visceral Fat and Liver Fat With Hyperuricemia // Arthritis Care & Research. 2016. № 4 (68). C. 553–561. 48. Zhang L. et al. Body mass index and serum uric acid level // Medicine. 2020. № 9 (99). C. e19418. 49. Zhang P. et al. Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial // European review for medical and pharmacological sciences. 2020. № 5 (24). C. 2719–2724. 50. Zhang Y. et al. Low-dose aspirin use and recurrent gout attacks // Annals of the Rheumatic Diseases. 2014. №2 (73). C. 385–390. 51. Zhang Y. et al. Association of hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study // Journal of Translational Medicine. 2020. №1 (18). C. 409. 52. Zuo T. [и др.]. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies // BMC Cardiovascular Disorders. 2016. № (16). C. 207-215 References [1-4]: 1. Fomin V.V, Morosova T.E., Tsurko V.V Giperurikemiya, podagra i vysokii kardiovaskulyarnyi risk – kak imi upravlyat' v klinicheskoi praktike [Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice]. Terapevticheskii arkhiv [Terapevticheskii arkhiv]. 2019. №12 (91), pp. 75–83. [In Russian] 2. Golovach I. Yu., Yehudina Y. D., Ter-Vartanian S. Kh. Bessimptomnaya giperurikemiya: tainye vzaimosvyazi, nevidimye effekty i potentsial'nye oslozhneniya [Asymptomatic hyperuricemia: secret relationships, invisible effects and potential complications]. Nauchno-prakticheskaya revmatologiya. [Rheumatology Science and Practice]. 2021. №6 (58), pp. 725–733. [In Russian] 3. Kobalava Z.D., Troitskaya E.A. Bessimptomnaya giperurikemiya: podkhody k lecheniyu v aspekte riska razvitiya serdechno-sosudistykh i pochechnykh zabolevanii [Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events]. Kardiologiya [Cardiology]. 2020. 60 (12), pp. 104-109. [In Russian] 4. Kudabaeva H.I. et al. Bessimptomnaya giperurikemiya u vzroslykh v ekologicheski neblagopoluchnykh raionakh Aktyubinskoi oblasti [Asymptomatic hyperuricemia in adults in ecologically unfavorable areas of the Aktobe region]. Meditsinskii zhurnal Zapadnogo Kazakhstana [West Kazakhstan Medical Journal]. 2018. №1 (57), рр. 4–9. [In Russian]
Number of Views: 43

Key words:

Bibliography link

Abisheva S.T., Batyrkhan T.E., Vinnik T.V. Risk factors for secondary hyperuricemia in arterial hypertension. Review // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 182-189. doi 10.34689/SH.2023.25.1.022

Авторизируйтесь для отправки комментариев